Jiangsu Recbio Technology Co., Ltd.
Status: Publicly traded
Direct answer
Jiangsu Recbio Technology Co., Ltd. is publicly traded on HKSE under the ticker 2179.HK.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent...
Can you invest in Jiangsu Recbio Technology Co., Ltd.?
Yes. Jiangsu Recbio Technology Co., Ltd. trades publicly on HKSE as 2179.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Jiangsu Recbio Technology Co., Ltd.
Detailed equity research is provided by MarketSnap.